Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Philip Morris International Inc. — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $60.55 (market cap $75.79B), while Philip Morris International Inc. trades at $200.2 (market cap $300.33B). The key difference: Philip Morris International Inc. is far larger — about 4× MONDELEZ INTERNATIONAL INC Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.5%). Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 107 Days and Philip Morris International Inc. for 85 Days on average.
| MDLZ | PM | |
|---|---|---|
Market Cap | $75.79B | $300.33B |
Volume | 6,277,523 | 3,935,700 |
Sector | Consumer Staples | Consumer Staples |
52-Week High | $64.99 | $200.50 |
52-Week Low | $51.51 | $144.33 |
Typical Hold Time | 107 Days | 85 Days |
Enterprise Value | $96.13B | $343.44B |
Dividend Yield | 3.5% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $59.38, down 0.4% with bearish technical signals but strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.73 beating expectations of $0.68. Revenue reached $38.54 billion in 2025, with an 8.86% net income margin and solid cash flow generation of $795 million. Analyst consensus remains strongly bullish with a $70.29 price target, representing 18% upside potential from current levels.
MDLZ presents a compelling investment case with consistent earnings outperformance, attractive dividend yield, and strong brand portfolio. However, investors face risks from cocoa cost volatility, competitive pressures, and margin compression. The stock's current valuation at 21.75 P/E offers reasonable entry point for long-term investors seeking defensive exposure in consumer staples with global growth potential.
Philip Morris International (PM) trades at $200.5, up 5.3% over 24 hours, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The company shows robust fundamentals with 2025 revenue of $40.65B and net income of $11.35B, supported by a 67.48% gross margin. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now over 40% of revenue, driving growth amid industry shifts.
Outlook is positive with analyst consensus at Buy (68%) and a $212.17 price target, though elevated P/E of 26.46 and regulatory risks in tobacco remain concerns. Earnings growth and smoke-free product adoption are key catalysts, but investors should monitor debt levels and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
